Comparison of TGFbR2 Down-regulation in Expanded HSCs on MBA/DBM Scaffolds Coated by UCB Stromal Cells

Overview

Journal In Vitro Cell Dev Biol Anim

Publisher Springer

Specialties Biology
Cell Biology

Date 2014 Dec 26

PMID 25539863

Citations 8

Authors

Zahra Sadat Hashemi

Mehdi Forouzandeh Moghadam

Masoud Soleimani

Affiliations

Soon will be listed here.

Abstract

Bone marrow transplants (BMTs) are mainly limited by a low number of CD34(+) cells. The transforming growth factor-beta (TGF-β) pathway downregulation is a key factor that increases cell self-renewal. In nature, hematopoietic stem cells (HSCs) are in a microenvironment, surrounded by cells in a three-dimensional (3D) configuration. The aim of this study is to investigate the association between a 3D culture and the delivery ratio of downregulation. Demineralized bone matrix (DBM) and mineralized bone allograft (MBA) scaffolds were coated using unrestricted somatic stem cells (USSCs) as the feeder layer. Umbilical cord blood (UCB)-CD34(+) cells were then ex vivo expanded in them and transfected by small interfering RNA (siRNA) against TGFbR2, a type 2 receptor in the TGF-β pathway. Finally, quantitative real-time PCR, flow cytometry, and clonogenic assay were performed. In a global comparison, we observed that the highest expansion ratio, lowest expression level, and the highest CD34 marker belonged to the simple 2D culture transfected group. This suggests that TGFbR2 downregulation in a 2D culture can be done more effectively. The siRNA delivery system and the transfection ratio in an ex vivo environment, which mimicks in vivo conditions, have low efficiency. Genetic modification of the cells needs free 3D spaces to enable better transfection.

Citing Articles

Doxorubicin-loaded NK exosomes enable cytotoxicity against triple-negative breast cancer spheroids.

Hashemi Z, Ghavami M, Mohammadi F, Shokrollahi Barough M, Shokati F, Asghari S Iran J Basic Med Sci. 2024; 27(12):1604-1615.

PMID: 39539445 PMC: 11556763. DOI: 10.22038/ijbms.2024.79378.17194.

Distinctive Expression of MetastamiRs in Breast Cancer Mesenchymal Stem Cells Isolated from Solid Tumor.

Hashemi Z, Moghadam M, Khalili S, Hashemi S, Sepehr K, Sadroddiny E Curr Stem Cell Res Ther. 2024; 19(11):1525-1534.

PMID: 38265389 DOI: 10.2174/011574888X272313231124063458.

Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art.

Hatami Z, Hashemi Z, Eftekhary M, Amiri A, Karpisheh V, Nasrollahi K Cancer Cell Int. 2023; 23(1):157.

PMID: 37543612 PMC: 10403883. DOI: 10.1186/s12935-023-02996-6.

Bioactivity of Exosomes Derived from Trained Natural Killer Cells versus Non-Trained One: More Functional and Antitumor Activity.

Mohammadi F, Hashemi Z, Sarrami Forooshani R, Alizadeh S Biomed Res Int. 2022; 2022:5396628.

PMID: 36060136 PMC: 9433262. DOI: 10.1155/2022/5396628.

miR-29b Regulates Lung Cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.

Zhang H, Wang R, Deng Q Comput Math Methods Med. 2022; 2022:3110330.

PMID: 36003920 PMC: 9393195. DOI: 10.1155/2022/3110330.

References

Ploemacher R, van Soest P, Boudewijn A . Autocrine transforming growth factor beta 1 blocks colony formation and progenitor cell generation by hemopoietic stem cells stimulated with steel factor. Stem Cells. 1993; 11(4):336-47. DOI: 10.1002/stem.5530110412. View

Emerson S . Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood. 1996; 87(8):3082-8. View

Gao L, Chen X, Zhang X, Liu Y, Kong P, Peng X . Human umbilical cord blood-derived stromal cell, a new resource of feeder layer to expand human umbilical cord blood CD34+ cells in vitro. Blood Cells Mol Dis. 2006; 36(2):322-8. DOI: 10.1016/j.bcmd.2005.12.036. View

Kasten P, Luginbuhl R, van Griensven M, Barkhausen T, Krettek C, Bohner M . Comparison of human bone marrow stromal cells seeded on calcium-deficient hydroxyapatite, beta-tricalcium phosphate and demineralized bone matrix. Biomaterials. 2003; 24(15):2593-603. DOI: 10.1016/s0142-9612(03)00062-0. View

Zauli G, Vitale M, Visani G, Marchisio M, Milani D, Capitani S . In vitro growth of human fetal CD34+ cells in the presence of various combinations of recombinant cytokines under serum-free culture conditions. Br J Haematol. 1994; 86(3):461-7. DOI: 10.1111/j.1365-2141.1994.tb04774.x. View

Liu W, Cao Y . Application of scaffold materials in tissue reconstruction in immunocompetent mammals: our experience and future requirements. Biomaterials. 2007; 28(34):5078-86. DOI: 10.1016/j.biomaterials.2007.07.028. View

Ohmizono Y, SAKABE H, Kimura T, Tanimukai S, Matsumura T, Miyazaki H . Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia. 1997; 11(4):524-30. DOI: 10.1038/sj.leu.2400588. View

Zhao Y, Lin H, Zhang J, Chen B, Sun W, Wang X . Crosslinked three-dimensional demineralized bone matrix for the adipose-derived stromal cell proliferation and differentiation. Tissue Eng Part A. 2008; 15(1):13-21. DOI: 10.1089/ten.tea.2008.0039. View

Alimoghaddam K, Ghavamzadeh A, Jahani M, Jalali A, Jorjani H, Iravani M . Hematopoietic stem cell transplantation in acute promyelocytic leukemia, experience in Iran. Arch Iran Med. 2011; 14(5):332-4. DOI: 008. View

10.

Behnia H, Khojasteh A, Soleimani M, Tehranchi A, Khoshzaban A, Keshel S . Secondary repair of alveolar clefts using human mesenchymal stem cells. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 108(2):e1-6. DOI: 10.1016/j.tripleo.2009.03.040. View

11.

De Bruyn C, Delforge A, Bron D, Ley P, De Hemptinne D, Stryckmans P . Modulation of human cord blood progenitor cell growth by recombinant human interleukin 3 (IL-3), IL-6, granulocyte-macrophage colony stimulating factor (GM-CSF) and stem cell factor (SCF) in serum-supplemented and serum-free medium. Stem Cells. 1994; 12(6):616-25. DOI: 10.1002/stem.5530120609. View

12.

Malafaya P, Silva G, Reis R . Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev. 2007; 59(4-5):207-33. DOI: 10.1016/j.addr.2007.03.012. View

13.

Montjovent M, Mark S, Mathieu L, Scaletta C, Scherberich A, Delabarde C . Human fetal bone cells associated with ceramic reinforced PLA scaffolds for tissue engineering. Bone. 2008; 42(3):554-64. DOI: 10.1016/j.bone.2007.10.018. View

14.

Chung H, Park T . Surface engineered and drug releasing pre-fabricated scaffolds for tissue engineering. Adv Drug Deliv Rev. 2007; 59(4-5):249-62. DOI: 10.1016/j.addr.2007.03.015. View

15.

Dutta R, Dutta A . Comprehension of ECM-cell dynamics: a prerequisite for tissue regeneration. Biotechnol Adv. 2010; 28(6):764-9. DOI: 10.1016/j.biotechadv.2010.06.002. View

16.

Conrad P, Emerson S . Ex vivo expansion of hematopoietic cells from umbilical cord blood for clinical transplantation. J Leukoc Biol. 1998; 64(2):147-55. DOI: 10.1002/jlb.64.2.147. View

17.

Zhang G, Suggs L . Matrices and scaffolds for drug delivery in vascular tissue engineering. Adv Drug Deliv Rev. 2007; 59(4-5):360-73. DOI: 10.1016/j.addr.2007.03.018. View

18.

Sakiyama-Elbert S, Hubbell J . Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 2000; 65(3):389-402. DOI: 10.1016/s0168-3659(99)00221-7. View

19.

Moioli E, Clark P, Xin X, Lal S, Mao J . Matrices and scaffolds for drug delivery in dental, oral and craniofacial tissue engineering. Adv Drug Deliv Rev. 2007; 59(4-5):308-24. PMC: 4035021. DOI: 10.1016/j.addr.2007.03.019. View

20.

Pournasr B, Mohamadnejad M, Bagheri M, Aghdami N, Shahsavani M, Malekzadeh R . In vitro differentiation of human bone marrow mesenchymal stem cells into hepatocyte-like cells. Arch Iran Med. 2011; 14(4):244-9. DOI: 0011144/AIM.004. View